Beyond Survival: Economic Analyses of Chemotherapy in Advanced, Inoperable NSCLC

ONCOLOGY

Volumn 12, Issue 2, 1998, Pages 199-209

  Mather, Dell ^a   Sullivan, Sean D ^a   Parasuraman, Trivandrum V ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; VINDESINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; SURVIVORS;

EID: 0031884722     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Cancer Facts & Figures - 1996. Atlanta, American Cancer Society, 1996.
2. Carney DN: Management (chemotherapy/ best supportive care) of advanced-stage non-small cell lung cancer. Semin Oncol 22:58-62, 1995.
3. Cojean I, Le Chevalier T: Chemotherapy of stage IIIB and IV non-small-cell lung cancer. Ann Oncol 6(suppl 3):S41-S44, 1995.
4. Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small cell lung cancer. Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477-482, 1988.
5. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III non-small-cell lung cancer. N Engl J Mett 323:940-945, 1990.
6. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991.
7. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 115:681-686, 1991.
8. Schaake-Koning C, Van dan Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer N Engl J Med 326:524-530, 1992.
9. Blanke C, Ansan R, Mantravadi R, et al: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier Oncology Group protocol. J Clin Oncol 13:1425-1429, 1995.
10. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
11. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311, 899-909, 1995.
12. Cormier Y, Bergeron D, LaForge J, et al: Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 50:845-849, 1982.
13. Quoix E, Dietemann A, Charbonneau J, et al: Disseminated non-small-cell lung cancer (NSCLC): A randomized trial of chemotherapy (CT) vs palliative care (PC). Lung Cancer 4(suppl):A127, 1988.
14. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988.
15. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care vs supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 63:1271-1278, 1989.
16. Woods RL, Williams CJ, Levi J, et al: A randomized trial of cisplatin and vindesine vs supportive care only in advanced non-small-cell lung cancer, Br J Cancer 61:608-611, 1990
17. Cellerino R, Tummarello D, Guidi F, et al: A randomized trial of alternating chemotherapy vs best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 9:1453-1461, 1991.
18. Kaasa S, Lund E, Thorud E, et al: Symptomatic treatment vs combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67:2443-2447, 1991.
19. Cartei G, Cartei F, Cantone A, et al: Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care vs supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 85:794-800, 1993.
20. Vokes EE, Bitran JD, Vogelzang NJ: Chemotherapy for non-small cell lung cancer: The continuing challenge. Chest 99:1326-1328, 1991.
21. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993.
22. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993.
23. Marino P, Pampallona S, Preatoni A, et al: Chemotherapy vs supportive care in advanced non small cell lung cancer: Results of a metaanalysis of the literature Chest 106:861-865, 1994.
24. Palmer MJ, O'Sullivan B, Steele R, et al: Controversies in the management of non-small cell lung cancer. The results of an expert surrogate study Radiother Oncol 19:17-28, 1990.
25. Lind SE, DelVecchio-Good MJ, Minkovitz CS, et al: Oncologists vary in their willingness to undertake anti-cancer therapies. Br J Cancer 64:391-395, 1991.
26. Maher EJ, Coia L, Duncan G, et al: Treatment strategies in advanced and metastatic cancer: Differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys 23:239-244, 1992.
27. Mackillop WJ, Dixon P, Zhou Y, et al. Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol 32:106-115, 1994.
28. Raby B, Pater J, Mackillop WJ: Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13:1904-1911, 1995.
29. Gold MR, Siegel JE, Russell LB, et al: Cost-Effectiveness in Health and Medicine. New York. Oxford University Press, 1996.
30. Stathopoulos GP, Malamos NA, Papakostas P, et al: Treatment of non-small cell lung cancer with cisplatin combination on outpatient basis: Effectiveness, toxicity and cost-benefit. Proc Am Soc Clin Oncol 14:A1181, 1995.
31. Khuri F, Daly B, Garcia-Moliner M, et al: A comprehensive analysis of the cost basis of non-small-cell lung cancer (NSCLC) care in a single academic institution. Proc Am Soc Clin Oncol 14:A905, 1995.
32. Ciott R, Gilis P, Martin C: Economic evaluation of the use of gemcitabine single agent in NSCLC in Belgium (abstract). Anti-Cancer Treatment, Sixth International Congress, p 75. Paris, France. February 6-9, 1996.
33. Williamson SK, Crowley JJ, Livingston RB, et al: Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Study. Invest New Drugs 13:67-71, 1995.
34. Rees GJG: Cost-effectiveness in oncology. Lancet 2:1405-1408, 1985.
35. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer J Clin Oncol 8:1301-1309, 1990.
36. Evans WK: Management of metastatic non-small-cell lung cancer and a consideration of cost. Chest 103(suppl 1):68S-71S, 1993.
37. Evans WK, Will BP: The cost of managing lung cancer in Canada. Oncology 9(suppl 11): 147-153, 1995.
38. Kennedy W, Reinharz D, Tessier G. et al: Cost utility of chemotherapy and best supportive care in non-small-cell lung cancer. Pharmacoeconomics 8:316-323, 1995.
39. Koch P, Johnson N, van Schaik J, et al: Gemcitabine Clinical and economic impact in inoperable non-small cell lung cancer. Anticancer Drugs 6(suppl 6) 49-54, 1995.
40. Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 13:2166-2173, 1995.
41. Copley-Merriman C, Corral J, King K, et al: Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer 14:45-61, 1996.
42. Copley-Merriman C, Martin C, Johnson N, et al: Economic value of gemcitabine in non-small-cell lung cancer. Semin Oncol 23:90-98, 1996
43. Evans WK: An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Semin Oncol 23(suppl 10):82-89, 1996
44. Palmer AJ, Brandt A: The cost-effectiveness of four cisplatm-containing chemotherapy regimens in the treatment of stages IIIB and IV non-small cell lung cancer: An Italian perspective. Monaldt Arch Chest Dis 51:279-288, 1996.
45. Vergnenègre A, Perol M, Pham E, et al: Cost analysis of hospital treatment-two Chemotherapic regimens for non-surgical non-small cell lung cancer. Lung Cancer 14:31-44, 1996.
46. Evans WK, Le Chevalier T: The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small-cell lung cancer. Eur J Cancer 32A: 2249-2255, 1996.
47. Weinstein MC, Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Meet 296:716-721, 1977.
48. Torrance GW, Feeny D: Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5:559-575, 1989.
49. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin vs. vindesine and cisplatin vs vinorelbine alone in advanced non-small-cell lung cancer. Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
50. Wolfson MC: POHEM - a framework for understanding and modeling the health of human populations. Proceedings of the Bureau of the Census Annual Research Conference. Arlington, Virginia, 261-282, 1992.
51. Detsky AS, Naglie G: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 113:147-154, 1990.
52. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 85:1460-1474, 1993.
53. Drummond M, Torrance G, Mason J: Cost-effectiveness league tables: More harm than good? Soc Sci Med 37:33-40, 1993.
54. Mackillop WJ, O'Sullivan B, Ward GK: Non-small cell lung cancer: How oncologists want to be treated. Int J Radiat Oncol Biol Phys 13:929-934, 1987.
55. O'Connor AMC, Boyd NF, Warde P, et al: Eliciting preferences for alternative drug therapies in oncology: Influence of treatment outcomes description, elicitation technique and treatment experience on preferences. J Chronic Dis 40:811-818, 1987.
56. O'Connor AM: Effects of framing and level of probability on patient's preferences for cancer chemotherapy. J Clin Epidemiol 42:119-126, 1989.
57. Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300:1458-1460, 1990.
58. Brundage MD, Davidson JR, Mackillop WJ: Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15:330-340, 1997.
59. Bennett CL, Smith TJ, George SL, et al: Free-riding and the prisoner's dilemma: Problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 13:2457-2463, 1995.
60. Bennett CL, Armitage JL, Buchner D, et al: Economic analyses in phase III clinical cancer trials. Cancer Invest 12:336-342, 1994.
61. Weeks JC: Special issues that arise in applying techniques of economic analysis to evaluation of cancer therapies. J Natl Cancer Inst Monogr 19:11-12, 1995.
62. Torfs K: Increasing interest in the integration of economic evaluation in cancer clinical trials. Forum 1:4, 1996.
63. Bennett CL, Armitage JL, LeSage S, et al: Economic analyses of clinical trials in cancer: Are they helpful to policy makers? Stem Cells (Dayt) 12-424-429, 1994.
64. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ: The BMJ Economic Evaluation Working Party. Br Med J 313:275-283, 1996.